Last $65.87 USD
Change Today -0.47 / -0.71%
Volume 3.8M
STJ On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

One St. Jude Medical Drive

Saint Paul, MN 55117

United States

Phone: 651-756-2000

Fax: 651-756-3301

itrode family of leads. This family includes single and dual column paddle leads that provide approximately two vertebral segments of coverage, such as Tripole leads, which feature a three-column electrode array and are designed to focus stimulation for improved targeting of low back pain; C-Series leads, shaped to mimic the curve of the epidural space of the spine and designed to facilitate lead placement and reduce lead migration; and the Penta lead, a five column lead, which is designed to provide improved stimulation control and specificity for focused stimulation therapy. Perc-paddle leads are a category of leads originated by the company with the advent of the Epiducer lead delivery system (European launch and FDA approval). The Epiducer system allows the percutaneous introduction of the company’s small profile S-Series paddle leads and/or multiple leads through a single needle stick. S-Series leads are designed to have the focused stimulation and stability of a paddle lead yet, with the Epiducer lead delivery system, could be introduced through a minimally invasive percutaneous procedure, such as a percutaneous lead. The company’s SCS systems are programmed with its Rapid Programmer platform. This system enables clinicians to test patients intra-operatively and program patients post-operatively. The Rapid Programmer platform consists of a palm-sized programmer that features a touch screen interface enabling clinicians to create multiple programs tailored for each patient's pain pattern. In addition to SCS to treat chronic pain, NMD could be used to treat other neurological conditions. DBS involves the placement of a lead or leads in targeted areas of the brain. The company entered the DBS market in Europe with its Libra and LibraXP DBS systems for treating the symptoms of Parkinson's disease, a neurological disorder that progressively diminishes a person's control over movement. The Brio IPG (European CE Mark approval), a small, long lasting rechargeable DBS device; the Guardian burr hole cap; and the Athena clinician programmer improve the company’s DBS offering in the European market. Its DBS systems are also marketed in Australia and certain Latin American countries. The company initiated a limited launch in Europe of the Genesis neurostimulation system for PNS of the occipital nerves for the management of the pain and disability associated with intractable chronic migraine. PNS therapy for this condition involves the delivery of mild electrical pulses to the occipital nerves that are located just beneath the skin at the back of the head. A small electrical lead or leads are placed under the skin and connected to the neurostimulator, which produces the pulses of stimulation. In 2012, the company expanded its PNS therapy for its chronic migraine headache portfolio to include the Eon family of neurostimulation systems. Marketing and Distribution The company’s products are sold in approximately 100 countries worldwide. The primary geographic markets for its products are the United States, Europe, Japan, and the Asia Pacific. In the United States, the company sells directly to healthcare providers primarily through a direct sales force. In Europe, it has direct sales organizations selling in 25 countries. In Japan, it sells directly to healthcare providers through a direct sales force and the company also continues to use longstanding independent distributor relationships. In the Asia Pacific, the company has direct sales organizations selling in eight countries, and it also utilizes independent distributors. Throughout the rest of the world, the company uses a combination of independent distributors and direct sales forces. Research and Development The company’s research and development expenses were $676 million in 2012. Seasonality Net sales in the third quarter (year ending December 2012) are lower than other quarters of the year as a result of patient tendencies to defer, if possible, procedures during the summer months and from the seasonality of the U.S. and European markets, where summer vacation schedules result in fewer procedures. Government Regulation The company’s pro

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STJ:US $65.87 USD -0.47

STJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $14.81 USD -0.04
CR Bard Inc $171.03 USD -5.91
Smith & Nephew PLC 1,191 GBp -9.00
Terumo Corp ¥2,941 JPY +35.00
Zimmer Holdings Inc $112.10 USD -0.42
View Industry Companies
 

Industry Analysis

STJ

Industry Average

Valuation STJ Industry Range
Price/Earnings 19.2x
Price/Sales 3.4x
Price/Book 4.5x
Price/Cash Flow 17.5x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ST JUDE MEDICAL INC, please visit www.sjm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.